Skip to main content
Fig. 4 | Trials

Fig. 4

From: A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

Fig. 4

H1-specific IgG antibody titers. H1-specific IgG levels were measured before first vaccination (study day 0) and at five subsequent study days. Shown are the medians for groups 1, 2 and 4. Error bars represent the interquartile range. Black arrows indicate vaccination time points. A dotted line indicates IgG measured at baseline. For each group, vaccination time points were compared using Kruskal-Wallis (overall effect) and, if p < 0.05, Mann-Whitney tests compared each post-vaccination time point to baseline (day 0). Asterisks indicate a significantly increased titer in group 4 at study days 98 and 224 compared to baseline (p = 0.0002 and 0.024)

Back to article page

Trials

ISSN: 1745-6215